耐性がん細胞はGPX4抑制に脆弱である
Matthew J Hangauer1,2,3, Vasanthi S Viswanathan4, Matthew J Ryan4
1Department of Microbiology and Immunology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, California 94143, USA.
Nature
|November 2, 2017
まとめ
脂質水酸化酵素GPX4 (グルタチオン過酸化酵素4) を標的にすることで,治療に抵抗するがんの持続細胞を排除できます. GPX4を阻害すると,選択的にこれらの細胞を殺し,腫瘍の再発と薬剤耐性を予防します.
科学分野:
- 腫瘍学
- 細胞生物学
- 薬剤耐性メカニズム
背景:
- 獲得した薬剤耐性はがん治療の有効性を制限し,不完全な反応と再発につながります.
- 非変異的メカニズム,特にがんの"持続性"の細胞の生存は,抵抗性の発達において極めて重要です.
- これらの持続細胞は薬剤耐性腫瘍の出現のための貯蔵庫を形成します.
研究 の 目的:
- 癌の細胞生存のメカニズムを調査し,治療標的を特定する.
- 持続性のある細胞が,以前に特定された治療に抵抗する細胞状態と依存関係を共有しているかどうかを判断する.
- 腫瘍の再発を防ぐために特定された依存症を標的とした治療の可能性を評価する.
主な方法:
- 様々な癌と薬物治療から得られた 持続細胞の分析
- 治療抵抗性および持続性のある細胞におけるグルタチオン過酸化酵素4 (GPX4) への依存性の評価
- GPX4機能の喪失と,その後の細胞死を含む in vitro 研究.
- 腫瘍再発に対するGPX4標的の影響を評価するマウスモデル.
主要な成果:
- 様々な癌と治療による持続細胞は,治療に抵抗する細胞状態を示します.
- この耐性状態は,生存のためにGPX4に依存します.
- GPX4機能の喪失は,選択的なフェロプトシス死をインビトロで誘導する.
- 臨床前のマウスモデルでは,GPX4をターゲットにすることで,腫瘍の再発を防ぐことができました.
結論:
- ガン細胞は,治療に抵抗する細胞と同様にGPX4に依存するようになる.
- GPX4を標的にすることは,持続的な細胞を排除し,薬剤耐性を克服するための有望な戦略です.
- GPX4の抑制は,がん患者の腫瘍再発を予防する治療法として用いられる.
さらに関連する動画
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
14.0K
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
8.5K
関連する概念動画
Cancer Stem Cells and Tumor Maintenance
4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
GPCR Desensitization
6.2K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.2K
